BioCentury: New cost-effectiveness model aims to better capture value of medicines to society

Sep 6

Written By Marshall Bursis

media

Marshall Bursis

PharmaExec: The Value of Care - Q&A With Peter Rubin, Executive Director at No Patient Left Behind

Measuring the damage: IRA’s impact on small molecule drug development